DUSA Pharmaceuticals' Actinic Keratosis PDT Treatment Is Tip Of Pipeline
This article was originally published in The Gray Sheet
Executive Summary
DUSA Pharmaceuticals plans to submit a premarket approval application supplement within the next two months for the commercial version of the firm's BLU-U light source used in conjunction with the Levulan Kerastick actinic keratoses therapy.
You may also be interested in...
DUSA Pharmaceuticals
Maker of Levulan photodynamic therapy and photodetection products receives FDA "approvable" letter for a PMA supplement for a commercial version of its BLU-U light source for use in conjunction with the Levulan Kerastick actinic keratoses therapy for the face and scalp. A BLU-U prototype gained approval in December 1999 in conjunction with a new drug application for Levulan (1"The Gray Sheet" Dec. 13, 1999, p. 17)
DUSA Pharmaceuticals
Maker of Levulan photodynamic therapy and photodetection products receives FDA "approvable" letter for a PMA supplement for a commercial version of its BLU-U light source for use in conjunction with the Levulan Kerastick actinic keratoses therapy for the face and scalp. A BLU-U prototype gained approval in December 1999 in conjunction with a new drug application for Levulan (1"The Gray Sheet" Dec. 13, 1999, p. 17)
Ablation Versus Hysterectomy For Menorrhagia Achieves Cost Savings
Performing endometrial ablation in lieu of hysterectomy for treatment of dysfunctional uterine bleeding (DUB) can provide savings in the managed care setting, according to a recent study published in the American Journal of Managed Care.